SCHEMBL28097890

SCHEMBL28097890

ClCn1ccc(C2CC2)n1

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
ALDH1A1 P00352 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
FAAH O00519 1/20 0.33
MGLL Q99685 1/20 0.33
CYP19A1 P11511 1/20 0.32
TLR9 Q9NR96 1/20 0.31
TLR8 Q9NR97 1/20 0.31
TLR7 Q9NYK1 1/20 0.31
NTRK1 P04629 5/20 0.31
KCNH2 Q12809 3/20 0.31
NTRK2 Q16620 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16877119 0.80 NPC1 (0.56) NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL21166146 0.80 NPC1 (0.60) NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL21471164 0.79 NPC1 (0.55) NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL23940711 0.77 NPC1 (0.57) NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL14786291 0.76 NPC1 (0.51) NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL23940953 0.76 NPC1 (0.55) NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL29277926 0.75 NPC1 (0.72) NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL1083341 0.74
SCHEMBL17663322 0.73 SMN1; SMN2 (0.53) NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL10887936 0.73 NPC1 (0.49) NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112135825-A Plasma kallikrein inhibitors and uses thereof 夏尔人类遗传性治疗公司 2020-12-25 CN disclosed
CN-103384672-B The substituted piperazine of N-pteridine and piperazine pteridinone 武田药品工业株式会社 2016-09-28 CN disclosed